ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · IEX Real-Time Price · USD
0.170
-0.008 (-4.61%)
At close: Apr 26, 2024, 4:00 PM
0.174
+0.004 (2.18%)
After-hours: Apr 26, 2024, 6:39 PM EDT
ReShape Lifesciences Revenue
In the year 2023, ReShape Lifesciences had annual revenue of $8.68M, a decrease of -22.79%. Revenue in the quarter ending December 31, 2023 was $1.98M, a -36.27% decrease year-over-year.
Revenue (ttm)
$8.68M
Revenue Growth
-22.79%
P/S Ratio
0.46
Revenue / Employee
$299,241
Employees
29
Market Cap
3.98M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.68M | -2.56M | -22.79% |
Dec 31, 2022 | 11.24M | -2.36M | -17.35% |
Dec 31, 2021 | 13.60M | 2.30M | 20.36% |
Dec 31, 2020 | 11.30M | 8.02M | 244.38% |
Dec 31, 2019 | 3.28M | -5.82M | -63.95% |
Dec 31, 2018 | 9.10M | -813.00K | -8.20% |
Dec 31, 2017 | 9.91M | 6.52M | 192.19% |
Dec 31, 2016 | 3.39M | -646.00K | -15.99% |
Dec 31, 2015 | 4.04M | 500.00K | 14.13% |
Dec 31, 2014 | 3.54M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Applied DNA Sciences | 9.00M |
Evoke Pharma | 5.18M |
Soligenix | 839.36K |
Aethlon Medical | 574.25K |
Finch Therapeutics Group | 107.00K |
RSLS News
- 26 days ago - ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System - GlobeNewsWire
- 7 weeks ago - ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX - GlobeNewsWire
- 2 months ago - ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX - GlobeNewsWire
- 3 months ago - ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX - GlobeNewsWire
- 4 months ago - ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives - GlobeNewsWire
- 4 months ago - ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX - GlobeNewsWire
- 5 months ago - ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds - GlobeNewsWire